AUPR506601A0 - Method of modulating the activity of calcium channels in cardiac cells and reagents therefor - Google Patents

Method of modulating the activity of calcium channels in cardiac cells and reagents therefor

Info

Publication number
AUPR506601A0
AUPR506601A0 AUPR5066A AUPR506601A AUPR506601A0 AU PR506601 A0 AUPR506601 A0 AU PR506601A0 AU PR5066 A AUPR5066 A AU PR5066A AU PR506601 A AUPR506601 A AU PR506601A AU PR506601 A0 AUPR506601 A0 AU PR506601A0
Authority
AU
Australia
Prior art keywords
modulating
activity
calcium channels
cardiac cells
reagents therefor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AUPR5066A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Australian National University
Original Assignee
Australian National University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Australian National University filed Critical Australian National University
Priority to AUPR5066A priority Critical patent/AUPR506601A0/en
Publication of AUPR506601A0 publication Critical patent/AUPR506601A0/en
Priority to JP2002589036A priority patent/JP2004535397A/ja
Priority to NZ529940A priority patent/NZ529940A/en
Priority to EP02721869A priority patent/EP1392344A4/en
Priority to CNA028120566A priority patent/CN1516596A/zh
Priority to PCT/AU2002/000608 priority patent/WO2002092119A1/en
Priority to CA002446839A priority patent/CA2446839A1/en
Priority to BR0210902-6A priority patent/BR0210902A/pt
Priority to US10/478,112 priority patent/US20050049198A1/en
Priority to KR10-2003-7014989A priority patent/KR20040002970A/ko
Priority to ZA200309727A priority patent/ZA200309727B/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9453—Cardioregulators, e.g. antihypotensives, antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
AUPR5066A 2001-05-17 2001-05-17 Method of modulating the activity of calcium channels in cardiac cells and reagents therefor Abandoned AUPR506601A0 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
AUPR5066A AUPR506601A0 (en) 2001-05-17 2001-05-17 Method of modulating the activity of calcium channels in cardiac cells and reagents therefor
KR10-2003-7014989A KR20040002970A (ko) 2001-05-17 2002-05-17 심장 세포에서 칼슘 채널의 활성 조절 방법 및 그것을위한 시약
CNA028120566A CN1516596A (zh) 2001-05-17 2002-05-17 调节心脏细胞中钙通道活性的方法及其试剂
NZ529940A NZ529940A (en) 2001-05-17 2002-05-17 Method of modulating the activity of calcium channels in cardiac cells and reagents therefor
EP02721869A EP1392344A4 (en) 2001-05-17 2002-05-17 METHOD FOR MODULATING THE ACTIVITY OF CALCIUM CHANNELS IN CARDIAC AND REAGENTS THEREFOR
JP2002589036A JP2004535397A (ja) 2001-05-17 2002-05-17 心細胞におけるカルシウムチャンネルの活性の調節法及びそのための試薬
PCT/AU2002/000608 WO2002092119A1 (en) 2001-05-17 2002-05-17 Method of modulating the activity of calcium channels in cardiac cells and reagents therefor
CA002446839A CA2446839A1 (en) 2001-05-17 2002-05-17 Method of modulating the activity of calcium channels in cardiac cells and reagents therefor
BR0210902-6A BR0210902A (pt) 2001-05-17 2002-05-17 Método de modulação da atividade de canais de cálcio em células cardìacas e reagentes para isso
US10/478,112 US20050049198A1 (en) 2001-05-17 2002-05-17 Method of modulating the activity of calcium channels in cardiac cells and reagents therefor
ZA200309727A ZA200309727B (en) 2001-05-17 2003-12-15 Method of modulating the activity of calcium channels in cardiac cells and reagents therefor.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPR5066A AUPR506601A0 (en) 2001-05-17 2001-05-17 Method of modulating the activity of calcium channels in cardiac cells and reagents therefor

Publications (1)

Publication Number Publication Date
AUPR506601A0 true AUPR506601A0 (en) 2001-06-07

Family

ID=3829046

Family Applications (1)

Application Number Title Priority Date Filing Date
AUPR5066A Abandoned AUPR506601A0 (en) 2001-05-17 2001-05-17 Method of modulating the activity of calcium channels in cardiac cells and reagents therefor

Country Status (11)

Country Link
US (1) US20050049198A1 (https=)
EP (1) EP1392344A4 (https=)
JP (1) JP2004535397A (https=)
KR (1) KR20040002970A (https=)
CN (1) CN1516596A (https=)
AU (1) AUPR506601A0 (https=)
BR (1) BR0210902A (https=)
CA (1) CA2446839A1 (https=)
NZ (1) NZ529940A (https=)
WO (1) WO2002092119A1 (https=)
ZA (1) ZA200309727B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5370969B2 (ja) * 2010-02-23 2013-12-18 国立大学法人金沢大学 心筋障害の検査方法
CN101812523B (zh) * 2010-04-09 2012-08-22 广州益善生物技术有限公司 Ryr1基因snp检测特异性引物、液相芯片和检测方法
CN109010799B (zh) * 2018-07-09 2021-07-06 沣潮医药科技（上海）有限公司 RyR2蛋白或RyR2重组蛋白在制备抗心力衰竭药物中的用途
CN109306011B (zh) * 2018-09-27 2021-08-03 中国人民解放军第二军医大学 靶向RyR2蛋白的胞内纳米抗体在制备抗心力衰竭药物中的用途
CN119876003B (zh) * 2025-01-21 2026-04-24 深圳大学 一种肌质网钙泵囊泡的分离纯化方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5691310A (en) * 1987-09-29 1997-11-25 Vesely; David L. Methods of treatment using proANF peptides
DE4110785A1 (de) * 1991-04-04 1992-10-08 Bayer Ag Gewebe-spezifische humane neuronale calcium-kanal-subtypen und deren verwendung
AU1890092A (en) * 1991-04-18 1992-11-17 Indiana University Foundation Novel ester derivatives of ryanodine and dehydroryanodine
JP2003510257A (ja) * 1999-09-22 2003-03-18 コグネティックス・インコーポレイテッド カッパ−コノトキシンｐｖｉｉａの使用
GB0005124D0 (en) * 2000-03-03 2000-04-26 Cellpep Sa Maurocalcin,analogues thereof and their therapeutical uses
US7105489B2 (en) * 2002-01-22 2006-09-12 Amylin Pharmaceuticals, Inc. Methods and compositions for treating polycystic ovary syndrome

Also Published As

Publication number Publication date
CN1516596A (zh) 2004-07-28
BR0210902A (pt) 2004-06-08
WO2002092119A1 (en) 2002-11-21
JP2004535397A (ja) 2004-11-25
EP1392344A4 (en) 2005-09-21
EP1392344A1 (en) 2004-03-03
ZA200309727B (en) 2005-08-01
US20050049198A1 (en) 2005-03-03
CA2446839A1 (en) 2002-11-21
KR20040002970A (ko) 2004-01-07
NZ529940A (en) 2006-08-31

Similar Documents

Publication Publication Date Title
AU6864698A (en) Surgical template and surgical method employing same
AU1201600A (en) Controlling gene expression in living cells
AU2569599A (en) Cells or tissues with increased protein factors and methods of making and using same
AU4965799A (en) Bioreactor and cell culturing processes using the bioreactor
AU2003230834A1 (en) Antagonists of il-21 and modulation of il-21-mediated t cell responses
AU3182999A (en) Methods of diagnosis and triage using cell activation measures
AU2002329951A1 (en) Fixed-dried red blood cells
AU2361695A (en) Red blood cell surrogate
AU2003211585A1 (en) Reaction cell and method of using the cell
AU2003256710A1 (en) Auto-stimulating cells and method for making and using the same
AU3510200A (en) Human dickkopf-related protein and nucleic acid molecules and uses therefor
AU2002326980A1 (en) Method of modulating or examining ku70 levels in cells
AU6895900A (en) Methods of modulating matrix metalloproteinase activity and uses thereof
AU2001292292A1 (en) Novel enzyme having beta-glucosidase activity and use thereof
AU4316899A (en) Method, reagent and kit for genotyping of human papillomavirus
AU2003220856A1 (en) Immobilized cells and liposomes and method of immobilizing the same
AU7332800A (en) Card construction, methods of making and using
AU3354499A (en) Human mekk proteins, corresponding nucleic acid molecules, and uses therefor
AU9569998A (en) Photo-spectrometers, methods of use and manufacture
AUPR506601A0 (en) Method of modulating the activity of calcium channels in cardiac cells and reagents therefor
AU2002366813A1 (en) Cardiac pacing method and system
AU2087799A (en) Diagnostic and therapeutic methods based upon valpha24jalphaq t cells
AU1089299A (en) Thin-profile or button-type battery circuits and constructions, methods of forming
AU2002309989A1 (en) Directed evolution of protein in mammalian cells
IL137197A0 (en) Modulation of cell proliferation, methods and reagents